A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)
- Citation:
- Lancet Oncol vol 19 (3) 416-426
- Year:
- 2018
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(18)30006-8.pdf
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 7
- Parents:
- 2678
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA041287, U10CA045808, U10CA047642, U10CA077440, U10CA007968, U10CA077651, U10CA180791, U10CA180833, U10CA180836, UG1CA189858
- Corr. Author:
- Authors:
- Sandra P. D'Angelo Michelle R. Mahoney Brian A. Van Tine James Atkins Mohammed M. Milhem Balkrishna N. Jahagirdar Cristina R. Antonescu Elise Horvath William D. Tap Gary K. Schwartz Howard Streicher
- Networks:
- COLUMBIA, IA018, LAPS-MN026, LAPS-MO011, LAPS-NY016, METROMIN, NC002
- Study
- Alliance-A091401
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: